Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. has announced a Commercialization Service Agreement with Hasten, under which its subsidiary will provide commercialization services for certain products in China. This agreement, effective from December 11, 2025, will initially last for three years with automatic renewals. The subsidiary will handle various services including distribution, marketing, and sales forecasting. A deposit of RMB100,000,000 will be paid to Hasten, refundable based on sales targets. This agreement reflects Everest Medicines’ strategic focus on expanding its market presence in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the fields of oncology, autoimmune disorders, and infectious diseases, primarily targeting the Chinese market.
Average Trading Volume: 3,418,931
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.29B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.